

June 11, 2008

Honorable Max Baucus Chairman Committee on Finance United States Senate Washington, DC 20510

Dear Mr. Chairman:

The Congressional Budget Office has prepared the enclosed table summarizing the budgetary effects of S. 3101, assuming adoption of an amendment transmitted by your staff (draft name "GOE08452.xml"). CBO estimates that S. 3101 with that proposed amendment would increase spending on physicians' and other services by \$19.8 billion over the 2008-2013 period and \$62.8 billion over the 2008-2018 period; those amounts would be offset by reductions in payments to other providers (primarily Medicare Advantage plans). Taken together, the bill would reduce direct spending by \$5 million over both the 2008-2013 and 2008-2018 periods, CBO estimates.

S. 3101, when amended, would avert a reduction to Medicare's physician fee schedule planned for July 1, 2008, by freezing those fees at their current levels for the remainder of the year and increasing them by 1.1 percent in January 2009. Beyond 2009, fees would be held at their current-law levels, necessitating a 21 percent reduction in 2010. The bill would also extend many expiring provisions of Medicare, expand Medicare's coverage of preventive services, and modify the rules governing eligibility for the Medicare Savings Program.

New spending under the bill would be offset largely by reductions in payments to and enrollment in Medicare Advantage plans. The bill, with the amendment, would phase out double payments for indirect medical education made to plans and hospitals for Medicare Advantage enrollees. It also would require private fee-for-service plans to adopt networks, with some exceptions, leading to decreases in enrollment and reduced outlays. Other savings would come from modifications to the Physician Assistance and Quality Initiative fund and changes to Medicare's payments for home oxygen therapy.

Honorable Max Baucus Page 2

I hope this information is helpful to you. The CBO staff contact for further information is Tom Bradley, who can be reached at 226-9010.

Sincerely,

Peter R. Orszag

Director

Enclosure

cc: Honorable Charles E. Grassley

Ranking Member

												2008-	2008-
							2014	2015	2016	2017	2018	2013	2018
	CHAN	GES IN	I DIRE	ECT SF	PENDI	NG							
TITLE I - MEDICARE													
Subtitle A. Beneficiary Improvements													
PART I - PREVENTION, MARKETING, AND QUALITY IMPROVEMENT													
101 Improvements to coverage of preventive services.	0	*	0.1	0.3	0.5	0.5	0.6	8.0	0.9	1.0	1.2	1.4	5.9
102 Elimination of discriminatory copayment rates for medicare													
outpatient psychiatric services.	0	0	*	0.1	0.1	0.2	0.4	0.5	0.5	0.5	0.6	0.5	3.0
103 Prohibitions and limitations on certain sales and marketing activities under Medicare Advantage plans and prescription drug													
plans.	0	0	0	0	0	0	0	0	0	0	0	0	0
104 Improvements to the Medigap program.	0	0	0	0	0	0	0	0	0	0	0	0	0
PART II - LOW-INCOME PROGRAMS													
111 Extension of qualifying individual (QI) program through December													
31, 2009.	0.4						•	•	•	_	•		
Medicaid	0.1		-0.1		0	0	0	0	0	0			
Medicare	•	0.3	0.1	•	0	0	0	0	0	0	0	0.5	0.5
112 Application of full LIS subsidy assets test under Medicare Savings	•	0.4		0.0	0.4	0.7	0.0	0.0		4.0		4.0	7.0
Program.	0	0.1	0.2		0.4	0.7	0.8	0.9	1.1	1.3	1.4	1.6	7.0
113 Eliminating barriers to enrollment.			Inc	luded i	n the e	stimate	e for se	ction 1	12				
114 Elimination of Medicare part D late enrollment penalties paid by	0	*	*	*	*	*	*		^	0	0	0.4	0.4
subsidy eligible individuals.	0	^					,	,	0	0	0	0.1	0.1
115 Eliminating application of estate recovery.	0	0	•	•	•	^	•	^	•	•	•	•	0.1
116 Exemptions from income and resources for determination of eligibility for low-income subsidy.			Inc	luded i	n the e	stimate	e for se	ction 1	12				
117 Judicial review of decisions of the Commissioner of Social													
Security under the Medicare part D low-income subsidy program.	0	0	0	0	0	0	0	0	0	0	0	0	0
118 Translation of model form.			Inc	luded i	n the e	stimate	e for se	ction 1	12				
119 Medicare enrollment assistance.			Inc	luded i	n the e	stimate	e for se	ction 1	12				

												2008-	2008-
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2013	2018
Subtitle B. Provisions Relating to Part A													
121 Expansion and extension of the Medicare Rural Hospital													
Flexibility Program.	0	0	0	0	0	0	0	0	0	0	0	0	0
122 Rebasing for sole community hospitals.	0	*	*	*	*	*	*	*	*	*	*	0.1	0.3
123 Demonstration project on community health integration models in													
certain rural counties.	0	0	0	0	0	0	0	0	0	0	0	0	0
124 Extension of the reclassification of certain hospitals.	0	0.2	*	0	0	0	0	0	0	0	0	0.2	0.2
125 Revocation of unique deeming authority of the Joint Commission.	0	0	0	0	0	0	0	0	0	0	0	0	0
Subtitle C. Provisions Relating to Part B													
PART I - PHYSICIANS' SERVICES													
131 Physician payment, efficiency, and quality improvements.	1.5	6.0	2.4	0	0	-3.2	-1.8	0	0	0	0	6.8	5.0
132 Incentives for electronic prescribing.	0	0	0.1	-0.1	-0.2	-0.3	-0.3	-0.3	-0.3	-0.2	-0.2	-0.4	-1.7
133 Expanding access to primary care services.	0.2	0.1	*	*	*	*	*	*	*	*	0.1	0.5	0.7
134 Extension of floor on Medicare work geographic adjustment under													
the Medicare physician fee schedule.	0.1	0.3	0.1	*	*	*	*	*	*	*	*	0.6	0.6
135 Imaging provisions.	0	0	*	*	0	0	0	0	0	0	0	*	*
136 Extension of treatment of certain physician pathology services													
under Medicare.	*	0.1	*	0	0	0	0	0	0	0	0	0.1	0.1
137 Accommodation of physicians ordered to active duty in the Armed													
Services.	*	*	*	*	*	*	*	*	*	*	*	*	*
138 Adjustment for Medicare mental health services.	*	*	0	0	0	0	0	0	0	0	0	*	*
139 Improvements for Medicare anesthesia teaching programs.	0	0	*	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.5

	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2008- 2013	2008- 2018
PART II - OTHER PAYMENT AND COVERAGE IMPROVEMENTS													
141 Extension of exceptions process for Medicare therapy caps.	0.1	0.7	0.4	0	0	0	0	0	0	0	0	1.2	1.2
142 Extension of payment rule for brachytherapy and therapeutic													
radiopharmaceuticals.	*	*	*	0	0	0	0	0	0	0	0	*	*
143 Speech-language pathology services.	0	*	*	*	*	*	*	*	*	*	*	*	0.1
144 Payment and coverage improvements for patients with chronic													
obstructive pulmonary disease and other conditions.	0	-0.1	-0.2	-0.2	-0.2	-0.2	-0.2	-0.2	-0.2	-0.3	-0.3	-0.9	-2.1
145 Revision of payment for power-driven wheelchairs.	0	-0.3	-0.1	*	*	*	*	-0.1	-0.1	-0.1	-0.1	-0.6	-0.8
146 Clinical laboratory tests.	0	*	-0.1	-0.1	-0.2	-0.2	-0.2	-0.3	-0.3	-0.3	-0.3	-0.6	-2.0
147 Improved access to ambulance services.	*	0.1	*	0	0	0	0	0	0	0	0	0.1	0.1
148 Extension and expansion of the Medicare hold harmless provision under the prospective payment system for hospital outpatient													
department (HOPD) services for certain hospitals. 149 Clarification of payment for clinical laboratory tests furnished by	*	0.1	*	0	0	0	0	0	0	0	0	0.1	0.1
critical access hospitals. 150 Adding certain entities as originating sites for payment of	0	*	*	*	*	*	*	*	*	0.1	0.1	0.1	0.3
telehealth services.	0	*	*	*	*	*	*	*	*	*	*	*	0.1
151 MedPAC study and report on improving chronic care													
demonstration programs.	0	0	0	0	0	0	0	0	0	0	0	0	0
152 Increase of FQHC payment limits.	0	0	*	*	*	*	*	*	*	*	*	0.1	0.1
153 Kidney disease education and awareness provisions.	0	0	*	*	*	*	*	*	*	*	*	*	*
154 Renal dialysis provisions.	0	*	0.1	-0.1	-0.1	*	0.1	0.2	0.3	0.5	0.6	-0.1	1.5
Subtitle D. Provisions Relating to Part C													
161 Phase-out of indirect medical education.	0	0	-0.7	-2.9	-3.8	-5.1	-5.8	-6.4	-7.6	-7.6	-7.6	-12.5	-47.5
162 Revisions To requirements for Medicare Advantage private fee- for-service plans.			lno	ludod i	in the e	ctimate	o for co						
163 Revisions to quality improvement programs.	0	0	0	iuueu i N		31111a16 0	0 () 101 Se	0	0	0	0	0	0
164 Revisions to quality improvement programs. 164 Revisions relating to specialized Medicare Advantage plans for	U	U	U	U	U	U	U	U	U	U	U	U	U
special needs individuals.	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	*	*	0.2	0.5
165 Limitation on out-of-pocket costs for dual eligibles and qualified medicare beneficiaries enrolled in a specialized Medicare	U	U	0.1	0.1	0.1	0.1	0.1	0.1	0.1			0.2	0.5
Advantage plan for special needs individuals.	0	0	0	0	0	0	0	0	0	0	0	0	0
166 Adjustment to the Medicare Advantage stabilization fund.	0	0	0	0	0	-1.3	-0.4	0	0	0	0	-1.3	-1.8
167 Access to Medicare reasonable cost contract plans.	0	0	*	*	0	0	0	0	0	0	0	*	*
168 MedPAC study and report on quality measures.	0	0	0	0	0	0	0	0	0	0	0	0	0
169 MedPAC study and report on Medicare Advantage payments.	0	0	0	0	0	0	0	0	0	0	0	0	0

	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2008- 2013	2008- 2018
Subtitle E. Provisions Relating to Part D													
PART I - IMPROVING PHARMACY ACCESS													
171 Prompt payment by prescription drug plans and MA–PD plans under part D.	0	0	*	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.7
172 Submission of claims by pharmacies located in or contracting with long-term care facilities.	0	0	0	0	0	0	0	0	0	0	0	0	0
173 Regular update of prescription drug pricing standard.	0	0	0	0	0	0	0	0	0	0	0	0	0
PART II - OTHER PROVISIONS													
175 Inclusion of barbiturates and benzodiazepines as covered part D													
drugs.	0	0	0	*	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.3	1.3
176 Formulary requirements with respect to certain categories or													
classes of drugs.	0	0	0	0	0	0	0	0	0	0	0	0	0
Subtitle F. Other Provisions													
181 Use of part D data.	0	0	0	0	0	0	0	0	0	0	0	0	0
182 Revision of definition of medically accepted indication for drugs.	0	*	*	*	*	*	*	*	*	*	*	*	*
183 Contract with a consensus-based entity regarding performance													
measurement.	0	*	*	*	*	0	0	0	0	0	0	*	*
184 Cost-sharing for clinical trials.	0	*	*	*	*	*	*	*	*	*	*	0.1	0.1
185 Addressing health care disparities.	0	0	0	0	0	0	0	0	0	0	0	0	0
186 Demonstration to improve care to previously uninsured.	0	0	*	*	*	0	0	0	0	0	0	*	*
187 Office of the Inspector General report on compliance with and enforcement of national standards on culturally and linguistically													
appropriate services (CLAS) in Medicare.	0	0	*	*	*	*	0	0	0	0	0	*	*
188 Medicare Improvement Funding.	0	*	*	*	*	1.1	4.4	6.0	6.0	6.0	3.0	1.2	26.4
TITLE II - MEDICAID													
201 Extension of transitional medical assistance (TMA) and													
abstinence education program.	*	0.6	8.0	0.1	*	*	*	*	*	0	0	1.5	1.5
202 Medicaid DSH extension.	*	*	*	0	0	0	0	0	0	0	0	0.1	0.1
203 Pharmacy reimbursement under Medicaid.	0	0.1	0	0	0	0	0	0	0	0	0	0.1	0.1
204 Administrative review of disallowances of Federal financial													
participation under Medicaid.	0	0	0	0	0	0	0	0	0	0	0	0	0

Figures are outlays, by fiscal year, in BILLIONS of dollars.

												2008-	2008-
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2013	2018
TITLE III - MISCELLANEOUS													
301 Extension of TANF supplemental grants through fiscal year	r 2009. 0	0.2	0.1	*	*	0	0	0	0	0	0	0.3	0.3
302 70 percent federal matching for foster care and adoption													
assistance for the District of Columbia.	0	*	*	*	*	*	*	*	*	*	*	*	0.1
303 Extension of Special Diabetes Grant Programs.	0	0	0.1	0.3	0.2	*	0	0	0	0	0	0.6	0.6
304 IOM reports on best practices for conducting systematic re	views												
of clinical effectiveness research and for developing clinical	al												
protocols.	0	*	*	0	0	0	0	0	0	0	0	*	*
Interactions													
Medicare Advantage interactions	0	0	0.9	0.1	0.1	-1.0	-0.5	0.2	0.3	0.3	0.4	0.1	0.9
Premium interactions /1	0	-2.2	-1.1	-0.2	*	0.9	0.4	-0.2	-0.3	-0.4	-0.5	-2.6	-3.6
102 Mental health services - Medicaid interaction	0	0	*	*	*	*	*	*	*	*	*	*	-0.2
132 Electronic prescribing - Part D interaction	0	*	*	*	*	-0.1	-0.1	-0.1	-0.1	-0.2	-0.2	-0.2	-0.8
Total, Changes in Direct Spending /2	2.1	6.5	3.7	-2.0	-2.8	-7.5	-2.1	1.6	0.8	1.2	-1.4	*	*

Notes:

- * = cost or savings of less than \$50 million.
- 1. Premium interactions do not include the effect of the "beneficiary premium protection" provision. That effect is included In the estimate for section 131.
- 2. The estimated net effect on direct spending over both the 2008-2013 and 2008-2018 periods is a reduction of less than \$50 million.